Plasma Collection for Leiomyosarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to identify early blood markers that indicate the effectiveness of chemotherapy for individuals with metastatic leiomyosarcoma, a cancer originating in smooth muscles that can spread. Researchers will examine changes in circulating tumor DNA (tiny bits of tumor DNA in the blood) to predict the cancer's response to treatment. Participants must provide blood samples through plasma collection and may also provide tumor tissue for further analysis. The trial seeks patients with leiomyosarcoma that cannot be surgically removed or has spread, who are beginning chemotherapy with drugs such as doxorubicin or gemcitabine/docetaxel.
As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the trial involves chemotherapy, it's important to discuss your current medications with the trial team to ensure there are no interactions.
Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on identifying biomarkers for metastatic leiomyosarcoma, a rare and aggressive cancer. Unlike traditional treatments that primarily involve surgery, chemotherapy, or radiation, this trial aims to enhance our understanding of the disease by analyzing plasma and tumor samples. By identifying specific biomarkers, researchers hope to pave the way for more personalized and effective treatment options in the future, potentially improving outcomes for patients with this challenging condition.
Who Is on the Research Team?
Scott Schuetze
Principal Investigator
University of Michigan Rogel Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Chemotherapy
Participants receive chemotherapy with blood samples collected for ctDNA analysis and tumor tissue analysis
Follow-up
Participants are monitored for safety and effectiveness after treatment, with analysis of ctDNA and tumor response
What Are the Treatments Tested in This Trial?
Interventions
- Plasma Collection
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan Rogel Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator